We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of IMARA Inc. (“IMARA” or the “Company”) (NASDAQ: IMRA)in connection with the proposed merger of the Company with Enliven Therapeutics, Inc. (“Enliven”). Under the terms of the merger agreement, IMARA will issue IMARA common stock as merger consideration in exchange for the cancellation of shares of capital stock of Enliven and Enliven will become a wholly owned subsidiary of IMARA. Upon completion of the transaction, IMARA shareholders are expected to own only approximately 16% of the combined company, while Enliven shareholders are expected to own approximately 84% of the combined company.
Weiss Law is investigating whether (i) IMARA’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the minority equity interest in the combined company under the proposed transaction is fair to IMARA’s shareholders, and (iii) all information.
September 26, 2023
We are investigating possible breaches of fiduciary duty and violations of the federal securities laws by, among others, the Board of Directors and senior officers of Origin Materials, Inc. (NASDAQ: ORGN) (“Origin” or the “Company”), concerning the Company’s business, operations, and prospects surrounding the construction of the Origin 2 commercial plant.
September 14, 2023
Weiss Law announces that on September 13, 2023, they filed a class action lawsuit in the United States District Court for the Southern District of New York (“Court”), captioned Zappia v. Myovant Sciences Ltd. et al. Case 1:23-cv-08097, on behalf of a class (“Class”) of individuals and entities that held common stock of Myovant Sciences, Ltd. (“Myovant”) as of the close of business on January 20, 2023 (“Class Period”), asserting claims under Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, and Securities and Exchange Commission Rule 14a-9, in connection with the acquisition of Myovant Sciences, Ltd. by Sumitovant Biopharma Ltd. for an unfair price.
September 11, 2023
We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Hostess Brands, Inc. (“Hostess” or the “Company”) (NASDAQ: TWNK), in connection with its acquisition by The J. M. Smucker Company (NYSE: SJM) (“Smucker”) via tender offer.